Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 2
2008 3
2009 10
2010 12
2011 11
2012 11
2013 12
2014 10
2015 7
2016 4
2017 5
2018 3
2019 6
2020 2
2021 1
2022 4
2023 3
2024 1
2025 1
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

84 results

Results by year

Filters applied: . Clear all
Page 1
Comparison of the Efficacy of Vibegron and Fesoterodine for Neurogenic Detrusor Overactivity in Individuals With Spinal Cord Lesion: A Single-Center Prospective Randomized Crossover Trial.
Takahashi R, Imada K, Maki T. Takahashi R, et al. Neurourol Urodyn. 2025 Nov;44(8):1545-1552. doi: 10.1002/nau.70136. Epub 2025 Aug 26. Neurourol Urodyn. 2025. PMID: 40855787 Clinical Trial.
Patients were randomly assigned to receive either vibegron (50 mg) or fesoterodine (4 mg) in a crossover design for 4 weeks each, with no washout period between treatments. ...At the end of the second 4-week period, participant survey results indicated that 58% preferred v …
Patients were randomly assigned to receive either vibegron (50 mg) or fesoterodine (4 mg) in a crossover design for 4 weeks each, wit …
Pharmacokinetic profile of fesoterodine.
Malhotra B, Guan Z, Wood N, Gandelman K. Malhotra B, et al. Int J Clin Pharmacol Ther. 2008 Nov;46(11):556-63. doi: 10.5414/cpp46556. Int J Clin Pharmacol Ther. 2008. PMID: 19000553 Clinical Trial.
OBJECTIVE: Fesoterodine is a new antimuscarinic agent for the treatment of overactive bladder. Following oral administration, fesoterodine is rapidly and extensively hydrolyzed by nonspecific esterases to its active moiety: 5-hydroxymethyl tolterodine (5-HMT). ...Th …
OBJECTIVE: Fesoterodine is a new antimuscarinic agent for the treatment of overactive bladder. Following oral administration, feso …
Long-term safety, tolerability and efficacy of fesoterodine treatment in subjects with overactive bladder symptoms.
Van Kerrebroeck PE, Heesakkers J, Berriman S, Padmanabhan Aiyer L, Carlsson M, Guan Z. Van Kerrebroeck PE, et al. Int J Clin Pract. 2010 Apr;64(5):584-93. doi: 10.1111/j.1742-1241.2010.02361.x. Epub 2010 Feb 19. Int J Clin Pract. 2010. PMID: 20201992 Clinical Trial.
AIMS: The aim of this study was to assess the long-term safety, tolerability and efficacy of fesoterodine treatment in subjects with overactive bladder (OAB) symptoms. METHODS: This was an open-label extension study of a 12-week, double-blind fesoterodine study. ... …
AIMS: The aim of this study was to assess the long-term safety, tolerability and efficacy of fesoterodine treatment in subjects with …
Fesoterodine treatment of pediatric patients with neurogenic detrusor overactivity: A 24-week, randomized, open-label, phase 3 study.
Kitta T, Darekar A, Malhotra B, Shahin MH, Jones P, Lindsay M, Mallen S, Nieto A, Crook TJ. Kitta T, et al. J Pediatr Urol. 2023 Apr;19(2):175.e1-175.e10. doi: 10.1016/j.jpurol.2022.11.020. Epub 2022 Nov 29. J Pediatr Urol. 2023. PMID: 36504158 Clinical Trial.
The safety extension phase evaluated fesoterodine 4 and 8 mg for a further 12 weeks, with patients in the oxybutynin arm allocated to fesoterodine 4 or 8 mg. ...In Cohort 2 (n = 57), fesoterodine 2 and 4 mg BIC treatment resulted in improvements in MCC from b …
The safety extension phase evaluated fesoterodine 4 and 8 mg for a further 12 weeks, with patients in the oxybutynin arm allocated to …
Population Pharmacokinetic and Pharmacodynamic Modeling of Fesoterodine in Pediatric Patients with Neurogenic Detrusor Overactivity.
Sano Y, Shoji S, Shahin M, Sweeney K, Darekar A, Malhotra BK. Sano Y, et al. Eur J Drug Metab Pharmacokinet. 2023 May;48(3):257-269. doi: 10.1007/s13318-023-00818-8. Epub 2023 Mar 9. Eur J Drug Metab Pharmacokinet. 2023. PMID: 36892754 Free PMC article. Clinical Trial.
BACKGROUND AND OBJECTIVE: Fesoterodine is a muscarinic receptor antagonist approved for the treatment of overactive bladder (OAB) in adults and neurogenic detrusor overactivity (NDO) in pediatric patients. This work aimed to characterize the population pharmacokinetics of …
BACKGROUND AND OBJECTIVE: Fesoterodine is a muscarinic receptor antagonist approved for the treatment of overactive bladder (OAB) in …
Comparison of fesoterodine and tolterodine in patients with overactive bladder.
Chapple CR, Van Kerrebroeck PE, Jünemann KP, Wang JT, Brodsky M. Chapple CR, et al. BJU Int. 2008 Nov;102(9):1128-32. doi: 10.1111/j.1464-410X.2008.07907.x. Epub 2008 Jul 21. BJU Int. 2008. PMID: 18647298 Clinical Trial.
OBJECTIVE: To compare, in a post hoc analysis of a phase III trial, the maximum recommended doses of fesoterodine (8 mg) and tolterodine (4 mg) for improving overactive bladder (OAB) symptoms and health-related quality of life (HRQoL), as fesoterodine effectively re …
OBJECTIVE: To compare, in a post hoc analysis of a phase III trial, the maximum recommended doses of fesoterodine (8 mg) and tolterod …
Comparison of solifenacin and fesoterodine in treatment of overactive bladder.
Ercan Ö, Köstü B, Bakacak M, Aytaç-Tohma Y, Çoşkun B, Avcı F, Efe E. Ercan Ö, et al. Saudi Med J. 2015 Oct;36(10):1181-5. doi: 10.15537/smj.2015.10.12016. Saudi Med J. 2015. PMID: 26446328 Free PMC article. Clinical Trial.
Group 1 (n=60) received 5 mg solifenacin per day, while Group 2 (n=59) received 4 mg fesoterodine per day. All the patients' OAB symptom scores (OABSS) in weeks 0, 4, and 12 were recorded. ...However, discontinuation of drugs due to side effects was more frequent in fes …
Group 1 (n=60) received 5 mg solifenacin per day, while Group 2 (n=59) received 4 mg fesoterodine per day. All the patients' OAB symp …
Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder.
Chapple C, Van Kerrebroeck P, Tubaro A, Haag-Molkenteller C, Forst HT, Massow U, Wang J, Brodsky M. Chapple C, et al. Eur Urol. 2007 Oct;52(4):1204-12. doi: 10.1016/j.eururo.2007.07.009. Epub 2007 Jul 17. Eur Urol. 2007. PMID: 17651893 Clinical Trial.
OBJECTIVE: To determine the efficacy, tolerability, and safety of fesoterodine in subjects with overactive bladder (OAB). METHODS: This was a multicentre, randomised, double-blind, placebo- and active-controlled trial with tolterodine extended release (ER) to assess the ef …
OBJECTIVE: To determine the efficacy, tolerability, and safety of fesoterodine in subjects with overactive bladder (OAB). METHODS: Th …
The pharmacokinetic profile of fesoterodine: similarities and differences to tolterodine.
Simon HU, Malhotra B. Simon HU, et al. Swiss Med Wkly. 2009 Mar 7;139(9-10):146-51. doi: 10.4414/smw.2009.12542. Swiss Med Wkly. 2009. PMID: 19145494 Free article. Clinical Trial.
BACKGROUND: Fesoterodine is a new antimuscarinic agent developed for the treatment of overactive bladder. ...If fesoterodine was taken following a high-fat breakfast, we observed small increases in Cmax and AUC. ...
BACKGROUND: Fesoterodine is a new antimuscarinic agent developed for the treatment of overactive bladder. ...If fesoterodine w …
A Double-blind, Randomised Four-way Crossover Study to Compare the Effects of Fesoterodine 4 and 8 mg Once Daily and Qxybutynin 5 mg Twice Daily After Steady-state Dosing Versus Placebo on Cognitive Function in Overactive Bladder-wet Patients over the Age of 75 Years with Mild Cognitive Impairment.
Rajabali S, Asaana P, Nazari S, Wagg A. Rajabali S, et al. Eur Urol Focus. 2024 Mar;10(2):325-331. doi: 10.1016/j.euf.2024.02.005. Epub 2024 Feb 23. Eur Urol Focus. 2024. PMID: 38402104 Clinical Trial.
This study examined the cognitive safety of fesoterodine in older adults with mild cognitive impairment (MCI) and OAB. METHODS: This four-way randomised crossover study examined the cognitive effects of fesoterodine 4 and 8 mg and oxybutynin 5 mg b.i.d. compared wit …
This study examined the cognitive safety of fesoterodine in older adults with mild cognitive impairment (MCI) and OAB. METHODS: This …
84 results